Results 171 to 180 of about 38,942 (318)

Intravitreal ranibizumab (Lucentis®) in the treatment of retinal angiomatous proliferation (RAP) [PDF]

, 2009
Lazaros Konstantinidis, Evangelia Mameletzi, Irmela Mantel, Jean‐Antoine Pournaras, Léonidas Zografos, Aude Ambresin   +5 more
openalex   +1 more source

Intravitreal ranibizumab for myopic choroidal neovascularization: 12-month results [PDF]

, 2010
PURPOSE: The purpose of this study was to evaluate the safety and efficacy of intravitreal ranibizumab after 12 months in the treatment of choroidal neovascularization secondary to pathologic myopia.
Cachulo, ML, Carneiro, A, Carvalheira, F, Murta, JN, Nascimento, J, Rito, LF, Rosa, P, Ruiz-Moreno, JM, Silva, RM   +8 more
core  

PEY3 RANIBIZUMAB (LUCENTIS®) IS A COST-EFFECTIVE TREATMENT OF AGE-RELATED MACULA DEGENERATION (AMD) IN THE GERMAN HEALTH CARE SYSTEM

, 2007
AS Neubauer, El Back, Theodore David Kuehn, VS Thomas   +3 more
openalex   +1 more source

Comparative study of 1+PRN ranibizumab versus bevacizumab in the clinical setting

Clinical Ophthalmology, 2012
Angela M Carneiro,1,2 Luis S Mendonça,1 Manuel S Falcão,1,2 Sofia L Fonseca,1 Elisete M Brandão,1 Fernando M Falcão-Reis1,21Department of Ophthalmology of Hospital de São João, Porto ...
Carneiro AM, Mendonça LS, Falcão MS, Fonseca SL, Brandão EM, Falcão-Reis FM   +5 more
doaj  

Intravitreal ranibizumab for choroidal neovascularisation secondary to angioid streaks [PDF]

, 2009
Seungbum Kang, Young‐Jung Roh
openalex   +1 more source

Intravitreal ranibizumab for choroidal neovascularization secondary to acute multifocal posterior placoid pigment epitheliopathy [PDF]

, 2009
Nikolaos Mavrakanas, Efstratios Mendrinos, Cyrus Tabatabay, Constantin J. Pournaras   +3 more
openalex   +1 more source

Intravitreal Ranibizumab for the Treatment of Choroidal Neovascularization Secondary to Endogenous Endophthalmitis [PDF]

, 2009
Shwu‐Jiuan Sheu
openalex   +1 more source

Ranibizumab treatment history as predictor of the switch-response to aflibercept: evidence for drug tolerance

Clinical Ophthalmology, 2018
Ali Dirani, Irmela Mantel Department of Ophthalmology, University of Lausanne, Jules Gonin Eye Hospital, Fondation Asile des Aveugles, Lausanne, Switzerland Purpose: To investigate whether tolerance to the anti-VEGF drug, ranibizumab, develops after ...
Dirani A, Mantel I
doaj  

PSS15 THE COST-EFFECTIVENESS OF RANIBIZUMAB (LUCENTIS®) IN TREATING PATIENTS WITH PREDOMINANTLY CLASSIC, MINIMALLY CLASSIC, AND OCCULT NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (AMD)

, 2008
Adam Turpcu, JW Hay
openalex   +1 more source

Pharmacotherapy of Retinal Diseases with Ranibizumab [PDF]

, 2009
Daniel F. Kiernan, Theodore K. Lin, Veeral Sheth, Rama D. Jager   +3 more
openalex   +1 more source